教育工作经历: 1. 2004-09 至 2008-07, 福建农林大学, 生物科学(微生物方向), 学士 2.2008-09 至 2011-07, 福建师范大学, 生物化学与分子生物学, 硕士 3.2016-09 至 2020-03, 西安交通大学, 生物学, 博士 4.2011-09 至 2013-02, 中国科学院物质结构研究所, 吴允昆课题组, 研究实习员 5.2013-03 至 2016-09, 福建医科大学, 孟超肝胆医院, 研究实习员 6.2016-09 至 2021-11, 福建医科大学, 孟超肝胆医院, 助理研究员 7.2021-11至今, 福建医科大学, 孟超肝胆医院, 副研究员 8.2021-01至今,福州大学孟超医学与交叉科学中心,副研究员
|
科研项目: (1) 国家自然科学基金委员会, 联合基金项目, U22A20328, 脾脏靶向新生抗原疫苗用于肝癌精准免疫治疗 研究, 2023-01-01 至 2026-12-31, 联合单位主持 (2) 国家自然科学基金委员会, 青年科学基金项目, 81802413, 环状RNA circADAMTS13/miRNA/ADAMTS13信 号轴在肝癌发生发展中的分子机制研究, 2019-01-01 至 2021-12-31, 主持 (3) 福建省科技厅, 福建省自然科学基金面上项目, 2022J011280, CD8组织驻留性T细胞介导肝癌免疫治疗的作用机制研究, 2022-03 至 2025-03, 主持 (4) 福建省科技厅, 福建省科技创新联合资金项目, 2020Y9044, 基于新生抗原疫苗的精准免疫疗法联合PD-1抗体治疗肝细胞癌的分子机制研究, 2021-08 至 2024-08, 主持 (5) 福州市科技局, 福州市对外科技合作项目, 2022-Y-006, 基于新生抗原多肽疫苗的综合免疫治疗体系改善胰腺癌治疗疗效的作用机制研究, 2022-06 至 2024-06, 主持 (6) 福州市科技局, 福州市科技计划项目, 2021-S-113, 基于新生抗原的精准免疫疗法对肝细胞癌的治疗作用机制研究, 2021-06 至 2024-06, 主持 (7) 福州市卫生健康系统, 福州市卫生健康系统科技计划团队项目, 2019-S-wt3, 基于无创的循环肿瘤DNA 液态活检技术实时追踪肝癌克隆结构变化的研究, 2019-06 至 2022-05, 主持 (8) 福建省科技厅, 福建省自然科学基金面上项目, 2017J01161, 循环肿瘤DNA评估肝癌异质性及追踪肿瘤发生发展的研究, 2017-04 至 2020-04, 主持
|
已发表论文:(*为通讯作者) (1) Chen Hengkai; Li Zhenli; Qiu Liman; Dong Xiuqing; Chen Geng; Shi Yingjun; Cai Linsheng;Liu Wenhan; Ye Honghao; Zhou Yang; Ouyang Jiahe; Cai Zhixiong C ; Liu Xiaolong ; Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infltration in preclinical hepatocellular carcinoma models, Journal for ImmunoTherapy of Cancer, 2022, 10: e004389 (2) Cai Zhixiong C ; Su Xiaoping; Qiu Liman; Li Zhenli; Li Xiaolou; Dong Xiuqing; Wei Fuqun; Zhou Yang; Luo Liuping; Chen Geng; Chen Hengkai; Wang Yingchao; Zeng Yongyi; Liu Xiaolong ; Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion, Molecular cancer, 2021, 2021(20): 164 (3) Cai Zhixiong C ; Zhang Jun; He Yijing; Xia Lin; Dong Xiuqing; Chen Gen; Zhou Yan; Hu Xinlei; Zhong Shen; Wang Yingchao; Chen Hengkai; Xie Dan; Liu Xiaolong; Liu Jingfeng ; Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma, ESMO Open, 2021, 6(1): 100021 (4) Cai Zhixiong C ; Chen Geng; Zeng Yongyi; Dong Xiuqing; Li Zhenli; Huang Yanbing; Xin Fuli;Qiu Liman; Xu Haipo; Zhang Wei; Su Xiaoping; Liu Xiaolong; Liu Jingfeng ; Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma, Clinical Cancer Research, 2019, 25(17): 5284-5294 (5) Cai Zhixiong C ; Xin Fuli; Wei Zuwu; Wu Ming; Lin Xinyi; Du Xiaofan; Chen geng; Zhang Da; Zhang Zhenxi; Liu Xiaolong; Yao Cuiping ; Photodynamic Therapy Combined with Antihypoxic Signaling and CpG Adjuvant as an In Situ Tumor Vaccine Based on Metal–Organic Framework Nanoparticles to Boost Cancer Immunotherapy, Advanced healthcare materials, 2019, 9(1):1900996 (6) Ying Liu, Bingheng Lu, Zhixiong Cai*, Recent Progress on Mg- and Zn-Based Alloys for Biodegradable Vascular Stent Applications, Journal of nanomaterials, 2019, 2019, 1310792. (7) Liman Qiu#, Yanbing Huang#, Zhenli Li#, Xiuqing Dong, Geng Chen, Haipo Xu, Yongyi Zeng, Zhixiong Cai*, Xiaolong Liu*, Jingfeng Liu*, Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma, Molecular oncology, 2018,13: 441-455. (8) Geng Chen #, Zhixiong Cai #, Zhenli. Li, Dong Xiuqing., Xu Haipo., Lin Jianling., Chen Lihong., Huqin Zhang, Xiaolong Liu *, Jingfeng Liu *. Clonal evolution in long-term follow-up patients with hepatocellular carcinoma., International Journal of Cancer, 2018,143: 2862-2870. (9) Zhenli Li #, Geng Chen #, Zhixiong Cai #, Xiuqing Dong, Liman Qiu, Haipo Xu, Yongyi Zeng, Xiaolong Liu* , Jingfeng Liu*, Genomic and transcriptional Profiling of tumor infiltrated CD8+ T cells revealed functional heterogeneity of antitumor immunity in hepatocellular carcinoma, OncoImmunology, 2018,8:e1538436. (10) Xiuqing Dong #, Geng Chen #, Zhixiong Cai #, Zhenli Li, Liman Qiu, Haipo Xu, Yuan Yuan., Xiaolong Liu*, Jingfeng Liu*, CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients., Cell. Physiol. Biochem., 2018, 47: 2602-2612. (11) Zhixiong Cai#, Geng Chen#, Yongyi Zeng, Xiuqing Dong, Minjie Lin, Xinhui Huang, Da Zhang, Xiaolong Liu*, Jingfeng Liu* , Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma, International Journal of Cancer, 2017,141: 977–985. (12) Zhixiong Cai#, Da Zhang#, Xinyi Lin, Yunzhu Chen, Ming Wu, Zuwu Wei, Zhenxi Zhang, Xiaolong Liu, Cuiping Yao, Glutathione responsive micelles incorporated with semiconducting polymer dots and doxorubicin for cancer photothermal-chemotherapy, Nanotechnology, 2017, 28: 425102. (13) Cancan Chen#, Gaoxiong Wang#, Xinhui Huang , Xiuqing Dong, Geng Chen , Mingjie Lin, Zhixiong Cai* and Yongyi Zeng*, Overexpression of galectin-4 promotes cell growth of hepatocellular carcinoma cells in vitro and in vivo, International Journal of Clinical and Experimental Pathology, 2017;10:10233-10242. (14) Zhixiong Cai, Yongyi Zeng, Bo Xu, Yunzhen Gao, Sen Wang, Jinhua Zeng, Lihong Chen, Aimin Huang, Xiaolong Liu* and Jingfeng Liu*, Galectin-4 serves as a prognostic biomarker for the early recurrence/metastasis of hepatocellular carcinoma, Cancer Science, 2015,105: 1510-1088. |